These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 476658)

  • 1. Enhancement of the nuclear reactivity of alkylating agents by prednisolone.
    Wilkinson R; Birbeck MS; Harrap KR
    Cancer Res; 1979 Oct; 39(10):4256-62. PubMed ID: 476658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of the toxicity and antitumour activity of alkylating drugs by steroids.
    Shepherd R; Harrap KR
    Br J Cancer; 1982 Mar; 45(3):413-20. PubMed ID: 7073935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Some effects of chlorambucil on the chromatin of Yoshida ascites sarcoma cells.
    Riches PG; Harrap KR
    Cancer Res; 1973 Feb; 33(2):389-93. PubMed ID: 4688885
    [No Abstract]   [Full Text] [Related]  

  • 4. The binding of (3H)chlorambucil to isolated nuclear proteins of the Yoshida ascites sarcoma.
    Sellwood SM; Riches PG; Harrap KR
    Biochem Soc Trans; 1975; 3(5):649-51. PubMed ID: 1193258
    [No Abstract]   [Full Text] [Related]  

  • 5. Correlation of increased acetate binding with alkylating agent resistance in Walker and Yoshida tumor cells.
    Pinsky SD
    Biochem Pharmacol; 1982 Dec; 31(24):3991-6. PubMed ID: 7159476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Experimental studies on the antitumor effect of progesterone and enhancement of the therapeutic effect of anticancer drugs by progesterone--from the aspect of zinc metabolism].
    Ujiie S; Mimata Y; Okuno M; Wakui A
    Gan To Kagaku Ryoho; 1989 Jul; 16(7):2423-8. PubMed ID: 2751319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The binding of [3H]chlorambucil to nuclear proteins of the Yoshida ascites sarcoma.
    Riches PG; Harrap KR
    Chem Biol Interact; 1975 Oct; 11(4):291-9. PubMed ID: 1175248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance patterns of Walker carcinosarcoma 256 and other rodent tumors to cyclophosphamide and L-phenylalanine mustard.
    Schmid FA; Otter GM; Stock CC
    Cancer Res; 1980 Mar; 40(3):830-3. PubMed ID: 7471099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ineffectiveness of a drug combination on Yoshida sarcoma and Walker carcinosarcoma 256 of the rat and on Ehrlich carcinoma of the mouse].
    Zeller WJ; Wiessler M; Adzersen KH
    Arzneimittelforschung; 1972 Mar; 22(3):575-7. PubMed ID: 5067931
    [No Abstract]   [Full Text] [Related]  

  • 10. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
    Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological studies of the mechanism of tumor-induced bone marrow cytolysis.
    DiStefano JF; Lysik R; Zucker S
    Cancer Res; 1979 Apr; 39(4):1193-8. PubMed ID: 421203
    [No Abstract]   [Full Text] [Related]  

  • 12. The interaction of bifunctional alkylating agents with the DNA of tumour cells.
    Harrap KR; Gascoigne EW
    Eur J Cancer (1965); 1976 Jan; 12(1):53-9. PubMed ID: 1269527
    [No Abstract]   [Full Text] [Related]  

  • 13. The selectivity of action of alkylating agents and drug resistance. I. Biochemical changes occurring in sensitive and resistant strains of the Yoshida ascites sarcoma following chemotherapy.
    Harrap KR; Hill BT
    Br J Cancer; 1969 Mar; 23(1):210-26. PubMed ID: 5768437
    [No Abstract]   [Full Text] [Related]  

  • 14. Preclinical studies and clinical correlation of the effect of alkylating dose.
    Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
    Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide-resistant Yoshida ascites tumor cells and their cross resistance to some alkylating agents.
    Gerhartz HH; Liss E; Schmidt H
    J Cancer Res Clin Oncol; 1979 Jul; 94(3):257-63. PubMed ID: 479265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
    Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD
    Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experimental animal studies on the regional perfusion of tumors of the extremities].
    Brock N; Niekamp T
    Arzneimittelforschung; 1968 Jan; 18(1):1-7. PubMed ID: 5754938
    [No Abstract]   [Full Text] [Related]  

  • 18. [Studies with Proresid (SP-I) in various innoculation tumors].
    Osswald H; Schmähl D
    Med Klin; 1966 Apr; 61(17):681-4. PubMed ID: 5995181
    [No Abstract]   [Full Text] [Related]  

  • 19. Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines.
    Tew KD; Bomber AM; Hoffman SJ
    Cancer Res; 1988 Jul; 48(13):3622-5. PubMed ID: 3288331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
    Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
    Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.